Spesolimab: A Novel Treatment for Pustular Psoriasis

Abstract

Keywords

spesolimab IL-36 pustular psoriasis generalized pustular psoriasis localized pustular psoriasis acrodermatitis continua of hallopeau

Get full access to this article

View all access options for this article.

References

Gooderham

MJ.

Van Voorhees

AS.

Lebwohl

. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907-919.doi:10.1080/1744666X.2019.1648209

Furue

Yamamura

Tsuji

et al. Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol. 2018;98(1):5-13.doi:10.2340/00015555-2808

Baum

Visvanathan

Bossert

. Treatment with spesolimab, an anti-interleukin-36 receptor antibody, in patients with generalized pustular psoriasis, is associated with the downregulation of biomarkers linked to innate, Th1/Th17 and neutrophilic pathways. ESDR meeting September 21; 2019; Bordeaux, France.

Bachelez

Choon

S-E.

Marrakchi

et al. Inhibition of the Interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981-983.doi:10.1056/NEJMc1811317

Khanskaya

Pinkstaff

Marino

. A phase 1 study of ANB019, an anti-IL-36 receptor monoclonal antibody, in healthy volunteers. EAACI Congress May 26–30; 2018; Munich, Germany.